Advisory Committee Rejects Avandia Vs. Actos Comparison Data
Executive Summary
FDA's advisory panel for the review of cardiovascular safety concerns with GlaxoSmithKline's Avandia refused to consider unvetted data on Takeda's competing thiazolidinedione Actos because the information has not yet been fully analyzed by FDA
You may also be interested in...
Avandia, Actos Comparative Safety Evaluation "Not Novel," FDA Says
FDA used the Avandia advisory committee to defend its view that marketing withdrawal decisions can be based on safety comparisons to other drugs approved for the same condition
Avandia, Actos Comparative Safety Evaluation "Not Novel," FDA Says
FDA used the Avandia advisory committee to defend its view that marketing withdrawal decisions can be based on safety comparisons to other drugs approved for the same condition
Arava, Avandia's Divergent Paths: FDA Strengthens Arava Label Warning
As FDA advisory committee debated the fate of Avandia, the agency bolsters liver warning on Arava, another drug David Graham suggested be removed from the market.